This study investigates the synergistic prognostic value of tumor bilaterality and BRAF mutation status in PTC recurrence risk stratification.<h4>Methods</h4>We retrospectively reviewed 974 consecutive PTC patients who were surgically treated in the First Affiliated Hospital of Zhejiang University School of Medicine. The gene discussed is BRAF; the disease is neoplasm.